Hong Kong Exchanges and Clearing Limited

FORM 3A - Director/Chief Executive Notice - Interests in Shares of Listed Corporation

Form Serial Number:

DA20230602E00124

1. Date of relevant event:

30/05/2023
(dd/mm/yyyy)

2. Date when director became aware of the relevant event/ interest in the shares (if later):

(dd/mm/yyyy)

3. Stock code:

02197

4. Name of listed corporation:

Clover Biopharmaceuticals, Ltd. - B

5. Class of shares:

Ordinary Shares

6. Number of issued shares in class:

1,293,806,733

7. Name of director (English) as printed on HKID Card/Passport:

(Surname)	Liang
(Other names)	Joshua G

10. Name of director (Chinese):

11. Chinese Character Code as printed on HKID Card:

24. Details of relevant event:

Brief description of relevant event

Capacity in which shares were/are held

Number of shares bought/sold or involved

Currency of transaction

On Exchange

Off Exchange

Before relevant event

After relevant event

Highest price (per share)

Average price (per share)

Average consideration (per share)

Consideration code

Long position

12041

The number of shares in which you are interested has reduced because:
expiry or cancellation without exercise of equity derivatives under which (choose one):
you had a right to take the underlying shares

2101	Beneficial owner

11,832,500

Short position

25. Total shares in listed corporation immediately before the relevant event:

	Total number of shares	Percentage figure (%)
Long position	250,547,684	19.37

26. Total shares in listed corporation immediately after the relevant event:

	Total number of shares	Percentage figure (%)
Long position	238,715,184	18.45

27. Capacity in which interests disclosed in Box 26 are held:

Code describing capacity

Number of shares

2101	Beneficial owner

Long position

18,480,937

2101	Beneficial owner

Long position

10,850,930

2501	Other (you must describe the capacity in the Supplementary Information box)

Long position

209,383,317

28. Further information in derivative interests in listed corporation :

Derivatives code

Exercise period (dd/mm/yyyy)

Consideration - if derivatives granted by listed corporation

Number of shares

Begins

Ends

Currency

Price for grant

Currency

Exercise price

Currency

Price on assignment

Long position

4108	Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)

USD

0.000

1,819,930

Long position

4105	Unlisted derivatives - Physically settled

31/03/2022

30/03/2032

USD

0.001

HKD

7.300

9,031,000

29. Further information in relation to interests of children under 18 and/or spouse:

Child/Spouse	Name of child/spouse	Number of shares

30. Further information in relation to interests of corporations controlled by Director:

Name of controlled corporation	Address and place of incorporation	Name of controlling person	% control	Direct interest (Y/N)	Number of shares

31. Further information in relation to interests held by Director jointly with another person:

Name of joint shareholder	Address	Number of shares

32. Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust:

Names of Trust	Address	Status code	Number of shares

33. Further information from a party to an agreement under Section 317 (Please see Notes for further information required):

Names of other parties	Address	Number of shares

Total number of shares in which a director is interested under sections 317 and 318

34. Supplementary information:

Box 24, Mr. Liang decided not to accept the Options and RSUs which granted on April 11, 2023. Box 27, pursuant to the acting-in-concert deed, Mr. Liang is deemed to be interested in 209,383,317 shares held by Dr. Liang Peng. Box 28, Mr. Liang currently holds RSUs representing 1,819,930 shares.

35. Log/Serial Number of the previous form:

36. Number of concert party document(s) under section 317 attached/uploaded:

Date of filing this Form 3A:

02/06/2023
(dd/mm/yyyy)